Short Interest in Medpace Holdings, Inc. (NASDAQ:MEDP) Decreases By 15.1%

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,240,000 shares, a decrease of 15.1% from the February 28th total of 1,460,000 shares. Based on an average daily volume of 308,400 shares, the days-to-cover ratio is presently 4.0 days. Currently, 5.0% of the company's stock are short sold.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd bought a new position in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace during the 4th quarter valued at approximately $31,000. Jones Financial Companies Lllp boosted its holdings in Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the period. Lindbrook Capital LLC grew its stake in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares in the last quarter. Finally, Assetmark Inc. raised its holdings in Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares during the period. Institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MEDP. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Medpace presently has an average rating of "Hold" and an average price target of $376.30.

Remove Ads

Medpace Stock Performance

MEDP stock traded down $17.00 during mid-day trading on Friday, hitting $287.11. The company had a trading volume of 833,195 shares, compared to its average volume of 307,847. The firm has a market cap of $8.75 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45. Medpace has a 12 month low of $282.42 and a 12 month high of $459.77. The stock's fifty day moving average price is $331.56 and its two-hundred day moving average price is $337.49.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.